The first episode, “Psychedelic Novelty – Before it was Cool,” introduces the company’s proprietary molecule MEAI VANCOUVER, Oct. 11, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind” or the “company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems…


Previous articlePsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial
Next articleCOMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day